The KCTD20 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This loss-of-function model enables investigation of KCTD20-dependent cellular processes. The polyclonal format comprises a heterogeneous pool of gene-disrupted cells, circumventing clonal selection bias and better reflecting the genetic diversity of tumor tissue. As a pooled knockout, it provides a robust system for functional genomics studies without the artifacts of clonal expansion.
The parental A-549 cell line was originally derived from a 58-year-old male patient with lung carcinoma and displays morphological and biochemical features of alveolar type II pneumocytes. It is a widely used model for non-small cell lung cancer (NSCLC), serving in studies of proliferation, apoptosis, metastasis, and chemoresistance. This well-characterized background enables dissection of gene functions specifically relevant to lung adenocarcinoma pathogenesis and drug responses.
KCTD20 encodes a substrate recognition adaptor for the CUL3-RING E3 ubiquitin ligase complex. It is believed to simultaneously interact with CUL3 and target proteins, presenting them for ubiquitination. The complex??s catalytic core??comprising RBX1 and E2 enzymes??catalyzes the addition of K48-linked polyubiquitin chains, which direct substrates to the 26S proteasome for degradation. Thus, KCTD20 modulates protein stability, influencing processes such as cell cycle regulation. Its upstream regulators are undetermined, though MYC and E2F1 are potential transcriptional activators; its downstream substrates remain unknown but likely include proteins governing oncogenic and tumor-suppressive pathways.
In A-549 NSCLC cells, KCTD20 disruption enables dissection of CUL3-RING ligase function in cancer. The ubiquitin-proteasome system is frequently altered in malignancies, and KCTD20-dependent degradation may control key regulators of proliferation and apoptosis. This knockout model permits systematic analysis of proteomic changes, cell growth effects, and chemosensitivity alterations, particularly to cisplatin. Consequently, it directly links E3 adaptor activity to lung cancer phenotypes and may reveal novel substrate-dependent oncogenic mechanisms.
Typical applications include validation of KCTD20 loss via western blotting and RT-qPCR, proliferation (MTT, BrdU) and apoptosis (Annexin V/PI) assays, cell cycle analysis by flow cytometry, and migration assays using Transwell systems. Ubiquitination experiments and co-immunoprecipitation of CUL3 help characterize ligase complex interactions. The cells are also suitable for proteomic substrate identification and cisplatin sensitivity profiling. For detailed product information, please contact Ascent Research.
